Search

Your search keyword '"A F, Abolonin"' showing total 2 results
Start Over Author "A F, Abolonin"
2 results on '"A F, Abolonin"'

1. Use of remaxol in the combination therapy of post-withdrawal disorders in alcoholic patients with comorbid liver damage

Author

N A Bokhan, A F Abolonin, I É Ankudinova, D I Kurgak, and A I Mandel'

Subjects
alcoholism, remaxol, metabolic disturbance, bilirubin, alanine aminotransferase, aspartate aminotransferase, anxiety, anhedonia, pathological craving for alcohol, comorbidity, Medicine
Abstract

Aim. To evaluate the efficacy of Remaxol used to treat post-withdrawal disorders in alcoholic patients with comorbid liver damage. Subjects and methods. The authors assessed the severity of clinical parameters, such as pathological craving and anhedonia, biochemical parameters (bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) in 120 patients aged 30-60 years in the stage of remission formation. The patients were divided into two groups: 1) 62 patients received Remaxol; 2) 58 persons took placebo (a comparative group). Results. The use of the drug caused an accelerated reduction in somato-autonomic symptoms and a decrease in affective strain and manifestations of anxiety with disactualization of a pathological alcohol craving ideator. The patients receiving remaxol showed a prompt improvement in some biochemical parameters: the levels of total and direct bilirubin halved; in Group 1, the multiplicity of a decrease in ALT and AST activities was 2.5 and 2.2 times versus 1.38 and 1.47 in Group 2. After the course of therapy, the symptoms of anhedonia diminished by 5.2 times in Group 1 and only by 2.4 times in Group 2. Conclusion. The positive changes induced by remaxol incorporated into the combination treatment are due to the polymodal effect of the drug on metabolic mechanisms in both the nervous system and liver. This double action promotes the increased efficiency of treatment and the creation of conditions for remission.

Published
2012

2. Comparative efficiency of Proproten-100 during the therapy of patients with alcoholism in the stage of therapeutic remission

Author

N A, Bokhan, A F, Abolonin, E N, Krylov, T P, Vetlugina, S A, Ivanova, and O I, Epstein

Subjects
Adult, Male, Alcoholism, Treatment Outcome, Anti-Anxiety Agents, S100 Proteins, Humans, Female, Middle Aged, Antibodies, Antidepressive Agents
Abstract

An open comparative clinical study evaluated the efficiency of Proproten-100 in reliving affective, somatovegetative, behavioral, and cognitive post-withdrawal disorders and manifestations of primary pathological alcohol addiction in patients with alcohol dependence in the stage of therapeutic remission. We compared the efficiency of Proproten-100 and standard symptomatic drugs. The preparation possessed anxiolytic, antidepressant, and vegetostabilizing properties, produced a moderate soporific effect, and had no sedative activity in patients with dysphoric depressions and psychopathic disorders. Proproten-100 was more effective during the therapy of patients with anxious and wistful depressions. Proproten-100 increased the contents of IgG and natural antibodies against S100 protein in the blood from patients. The preparation did not cause side effect or development of tolerance. Proproten-100 has psychotropic properties and holds much promise for long-term treatment of patients with alcohol dependence to reduce the incidence of recurrences.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results